Chapter 1. Introduction
1.1. Report Description And Scope
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
Chapter 2. Executive Summary
2.1. Global Oral Anti-Diabetic Market, 2016 - 2022 (USD Billion)
2.2. Global Oral Anti-Diabetic Market: Snapshot
Chapter 3. Oral Anti-Diabetic Market Dynamics
3.1. Introduction
3.2. Value Chain Analysis
3.3. Market Drivers
3.3.1. Global Oral Anti-Diabetic Market Drivers: Impact Analysis
3.3.2. Rising Prevalence Of Diabetes Mellitus
3.3.3. Increase In Obesity
3.4. Market Restraints
3.4.1. Global Oral Anti-Diabetic Market Restraints: Impact Analysis
3.4.2. High Cost of Drugs
3.5. Opportunities
3.5.1. Market Strength
3.6. Porters Five Forces Analysis
3.6.1. Bargaining Power Of Suppliers
3.6.2. Bargaining Power Of Buyers
3.6.3. Threat From New Entrants
3.6.4. Threat From New Substitutes
3.6.5. Degree Of Competition
3.7. Market Attractiveness Analysis
3.7.1. Market Attractiveness Analysis, By Drug Class Segment
3.7.2. Market Attractiveness Analysis, By Regional Segment
Chapter 4. Global Oral Anti-Diabetic Market Competitive Landscape
4.1. Company Market Share, 2016 (Subject To Data Availability)
4.2. Strategic Development
4.2.1. Acquisitions Mergers
4.2.2. New Type Launch
4.2.3. Agreements, Partnerships, Collaborations And Joint Ventures
4.2.4. Research And Development, Regional Expansion
4.3. Type Portfolio
Chapter 5. Global Oral Anti-Diabetic Market Drug Class Analysis
5.1. Global Oral Anti-Diabetic Market: Drug Class Segment Overview
5.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Drug Class, 2016 And 2022
5.2. Sulfonylureas
5.2.1. Global Sulfonylureas Market, 2016 2022 (USD Billion)
5.2.2. Glimepiride
5.2.2.1. Glimepiride Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
5.2.3. Gliclazide
5.2.3.1. Gliclazide Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
5.2.4. Glyburide
5.2.4.1. Glyburide Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
5.2.5. Others
5.2.5.1. Others Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
5.3. Meglitinides
5.3.1. Global Meglitinides Market, 2016 2022 (USD Billion)
5.3.2. Repaglinide
5.3.2.1. Repaglinide Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
5.3.3. Nateglinide
5.3.3.1. Nateglinide Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
5.4. Biguanides
5.4.1. Global Biguanides Market, 2016 2022 (USD Billion)
5.4.2. Metformin
5.4.2.1. Metformin Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
5.4.3. Others
5.4.3.1. Others Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
5.5. Alpha-glucosidase inhibitors
5.5.1. Global Alpha-glucosidase inhibitors Market, 2016 2022 (USD Billion)
5.5.2. Acarbose
5.5.2.1. Acarbose Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
5.5.3. Voglibose
5.5.3.1. Voglibose Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
5.5.4. Others
5.5.4.1. Others Oral Anti-Diabetic Market Revenue, 2016 2022 (USD Billion)
Chapter 6. Global Oral Anti-Diabetic Market Regional Segment Analysis
6.1. Global Oral Anti-Diabetic Market: Regional Overview
6.1.1. Global Oral Anti-Diabetic Market Revenue Share, By Region, 2016 And 2022
6.2. North America
6.2.1. North America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022, (USD Billion)
6.2.2. U.S.
6.2.2.1. U.S. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
6.2.3. Canada
6.2.3.1. Canada Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
6.3. Europe
6.3.1. Europe Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
6.3.2. Germany
6.3.2.1. Germany Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022, (USD Billion)
6.3.3. France
6.3.3.1. France Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022, (USD Billion)
6.3.4. U.K.
6.3.4.1. U.K. Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
6.4. Asia Pacific
6.4.1. Asia Pacific Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
6.4.2. China
6.4.2.1. China Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
6.4.3. Japan
6.4.3.1. Japan Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
6.4.4. India
6.4.4.1. India Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
6.5. Latin America
6.5.1. Latin America Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
6.5.2. Brazil
6.5.2.1. Brazil Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
6.6. Middle East And Africa
6.6.1. Middle East And Africa Oral Anti-Diabetic Market Revenue, By Drug Class, 2016 2022 (USD Billion)
Chapter 7. Company Profile
7.1. Abbott Laboratories
7.1.1. Overview
7.1.2. Financials
7.1.3. Product Portfolio
7.1.4. Business Strategy
7.1.5. Recent Developments
7.2. Biocon, Ltd
7.2.1. Overview
7.2.2. Financials
7.2.3. Product Portfolio
7.2.4. Business Strategy
7.2.5. Recent Developments
7.3. Eli Lilly and Company
7.3.1. Overview
7.3.2. Financials
7.3.3. Product Portfolio
7.3.4. Business Strategy
7.3.5. Recent Developments
7.4. Sun Pharma Industries, Ltd.
7.4.1. Overview
7.4.2. Financials
7.4.3. Product Portfolio
7.4.4. Business Strategy
7.4.5. Recent Developments
7.5. Novo Nordisk A/S
7.5.1. Overview
7.5.2. Financials
7.5.3. Product Portfolio
7.5.4. Business Strategy
7.5.5. Recent Developments
7.6. Pfizer
7.6.1. Overview
7.6.2. Financials
7.6.3. Product Portfolio
7.6.4. Business Strategy
7.6.5. Recent Developments
7.7. Sanofi
7.7.1. Overview
7.7.2. Financials
7.7.3. Product Portfolio
7.7.4. Business Strategy
7.7.5. Recent Developments
7.8. Novartis
7.8.1. Overview
7.8.2. Financials
7.8.3. Product Portfolio
7.8.4. Business Strategy
7.8.5. Recent Developments
7.9. Merck Group
7.9.1. Overview
7.9.2. Financials
7.9.3. Product Portfolio
7.9.4. Business Strategy
7.9.5. Recent Development
